
Anti-MLLN-TerminusMonoclonalAntibody
MLL(MixedLineageLeukemia)isaproto-oncogenethatismutatedinavarietyofacuteleukemias.MLLisproteolyticallyprocessedinto2fragments,MLLNandMLLC,thatdisplayoppositetranscriptionalproperties.ProcessedMLLNandMLLC
associatewitheachotherviaN-terminalandC-terminalintramolecularinteractiondomains.MLLprocessingoccursrapidlyaftertranslationandisfollowedby
phosphorylationofMLLC.MLLNdisplays
transcriptionalrepressionactivity,whereasMLLChasstrongtranscriptionalactivationproperties.Leukemia-associatedMLLfusionproteinslacktheMLLprocessingsites,donotundergocleavage,andareunabletointeractwithMLLC.These
observationssuggestthatposttranslationalmodificationsofMLLmaybeinvolvedinregulatingMLLactivityasatranscriptionfactor,andthisaspectofitsfunctionisperturbedbyleukemogenicfusions.
ThisantibodyrecognizeshumanandmouseMLLN.
APPLICATIONSImmunoblotting:useat2ug/ml.Abandof
~300kDaisdetected.
K562cellnuclearextractwith#34041at2ug/ml.
Immunoprecipitation:use2-10ugper500ul(1-3mg/ml)ofcelllysate.
Thesearerecommendedconcentrations.Endusersshoulddetermineoptimalconcentrationsfortheirapplications.
Positivecontrol:K562celllysate.
DiluteinPBSormediumthatisidenticaltothatusedintheassaysystem.
Thisantibodyisstableforatleastone(1)yearat-20oC.Avoidmultiplefreeze-thawcycles.
YokoyamaAetal.2002Blood100:3710-
3718.
YokoyamaAetal.2005Cell123:207-218.
Forinvitroinvestigationaluseonly.Notintendedfordiagnosticortherapeuticapplications.